# A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

> **NCT05736406** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hemerion Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Primary Glioblastoma

## Interventions

- **COMBINATION_PRODUCT:** 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2
- **COMBINATION_PRODUCT:** 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2

## Key facts

- **NCT ID:** NCT05736406
- **Lead sponsor:** Hemerion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2025-12
- **Final completion:** 2026-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736406, "A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05736406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*